These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Ittner LM; Fath T; Ke YD; Bi M; van Eersel J; Li KM; Gunning P; Götz J Proc Natl Acad Sci U S A; 2008 Oct; 105(41):15997-6002. PubMed ID: 18832465 [TBL] [Abstract][Full Text] [Related]
8. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). Gibbons GS; Kim SJ; Robinson JL; Changolkar L; Irwin DJ; Shaw LM; Lee VM; Trojanowski JQ Acta Neuropathol Commun; 2019 Mar; 7(1):34. PubMed ID: 30832741 [TBL] [Abstract][Full Text] [Related]
9. Frontotemporal lobar degeneration: diversity of FTLD lesions. Seilhean D; Bielle F; Plu I; Duyckaerts C Rev Neurol (Paris); 2013 Oct; 169(10):786-92. PubMed ID: 24035575 [TBL] [Abstract][Full Text] [Related]
10. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration. Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339 [TBL] [Abstract][Full Text] [Related]
11. Sporadic four-repeat tauopathy with frontotemporal lobar degeneration, Parkinsonism, and motor neuron disease: a distinct clinicopathological and biochemical disease entity. Fu YJ; Nishihira Y; Kuroda S; Toyoshima Y; Ishihara T; Shinozaki M; Miyashita A; Piao YS; Tan CF; Tani T; Koike R; Iwanaga K; Tsujihata M; Onodera O; Kuwano R; Nishizawa M; Kakita A; Ikeuchi T; Takahashi H Acta Neuropathol; 2010 Jul; 120(1):21-32. PubMed ID: 20140439 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological correlations in behavioural variant frontotemporal dementia. Perry DC; Brown JA; Possin KL; Datta S; Trujillo A; Radke A; Karydas A; Kornak J; Sias AC; Rabinovici GD; Gorno-Tempini ML; Boxer AL; De May M; Rankin KP; Sturm VE; Lee SE; Matthews BR; Kao AW; Vossel KA; Tartaglia MC; Miller ZA; Seo SW; Sidhu M; Gaus SE; Nana AL; Vargas JNS; Hwang JL; Ossenkoppele R; Brown AB; Huang EJ; Coppola G; Rosen HJ; Geschwind D; Trojanowski JQ; Grinberg LT; Kramer JH; Miller BL; Seeley WW Brain; 2017 Dec; 140(12):3329-3345. PubMed ID: 29053860 [TBL] [Abstract][Full Text] [Related]
13. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils. Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461 [TBL] [Abstract][Full Text] [Related]
14. Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature. Przybyla M; van Eersel J; van Hummel A; van der Hoven J; Sabale M; Harasta A; Müller J; Gajwani M; Prikas E; Mueller T; Stevens CH; Power J; Housley GD; Karl T; Kassiou M; Ke YD; Ittner A; Ittner LM Brain; 2020 Jun; 143(6):1889-1904. PubMed ID: 32375177 [TBL] [Abstract][Full Text] [Related]
15. CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. Ke YD; Chan G; Stefanoska K; Au C; Bi M; Müller J; Przybyla M; Feiten A; Prikas E; Halliday GM; Piguet O; Kiernan MC; Kassiou M; Hodges JR; Loy CT; Mattick JS; Ittner A; Kril JJ; Sutherland GT; Ittner LM J Biol Chem; 2019 Sep; 294(38):14149-14162. PubMed ID: 31366728 [TBL] [Abstract][Full Text] [Related]
16. β-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates. Woo JA; Liu T; Fang CC; Castaño MA; Kee T; Yrigoin K; Yan Y; Cazzaro S; Matlack J; Wang X; Zhao X; Kang DE; Liggett SB Proc Natl Acad Sci U S A; 2020 Mar; 117(9):5006-5015. PubMed ID: 32071246 [TBL] [Abstract][Full Text] [Related]
17. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Irwin DJ; Cairns NJ; Grossman M; McMillan CT; Lee EB; Van Deerlin VM; Lee VM; Trojanowski JQ Acta Neuropathol; 2015 Apr; 129(4):469-91. PubMed ID: 25549971 [TBL] [Abstract][Full Text] [Related]
18. Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia. Warmus BA; Sekar DR; McCutchen E; Schellenberg GD; Roberts RC; McMahon LL; Roberson ED J Neurosci; 2014 Dec; 34(49):16482-95. PubMed ID: 25471585 [TBL] [Abstract][Full Text] [Related]
19. Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration. Taylor LM; McMillan PJ; Liachko NF; Strovas TJ; Ghetti B; Bird TD; Keene CD; Kraemer BC Mol Neurodegener; 2018 Feb; 13(1):7. PubMed ID: 29409526 [TBL] [Abstract][Full Text] [Related]
20. Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration. Melis V; Zabke C; Stamer K; Magbagbeolu M; Schwab K; Marschall P; Veh RW; Bachmann S; Deiana S; Moreau PH; Davidson K; Harrington KA; Rickard JE; Horsley D; Garman R; Mazurkiewicz M; Niewiadomska G; Wischik CM; Harrington CR; Riedel G; Theuring F Cell Mol Life Sci; 2015 Jun; 72(11):2199-222. PubMed ID: 25523019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]